CIK 0001601830
- Large accelerated filer
RECURSION PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RXRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464099738
- Phone
- +1 385-269-0203
- Business address
- 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
- Former names
- Recursion Pharmaceuticals, LLC
- 3 Insider Initial Statement of Ownership
- 4 Planned sale Director sold 220,000 shares at $4.36 ($959,200)
- 4 Planned sale Director sold 40,000 shares at $4.25 ($170,000)
- 4 Grant or award Director acquired 3,571 shares (grant or award)
- 4 Grant or award Director acquired 2,381 shares (grant or award)
- 4 Planned sale Chief Financial Officer sold 21,383 shares at $4.18 ($89,381)
- 4 Planned sale Chief R&D Commercial Officer sold 124,403 shares at $4.41 ($548,592)
- 4 Planned sale Chief Executive Officer sold 40,000 shares at $4.50 ($180,000)
- 4 Shares withheld for taxes Chief Financial Officer gave up 7,057 shares (to pay taxes)
- 4 Planned sale Chief Executive Officer sold 40,000 shares at $4.63 ($185,200)
- 4 Planned sale Director sold 220,000 shares at $4.37 ($961,400)
- 4 Shares withheld for taxes Chief Financial Officer gave up 2,271 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Financial Officer gave up 11,908 shares (to pay taxes)
- 4 Shares withheld for taxes Chief R&D Commercial Officer gave up 17,584 shares (to pay taxes)
- 4 Planned sale Chief Executive Officer sold 40,000 shares at $4.16 ($166,400)
- 4 Grant or award Chief R&D Commercial Officer acquired 84,925 shares (grant or award)
- 4 Planned sale Chief Executive Officer sold 40,000 shares at $5.21 ($208,400)
- 4 Planned sale Chief Executive Officer sold 100,000 shares at $5.70 ($570,000)
- 4 Planned sale Chief Executive Officer sold 100,000 shares at $6.04 ($604,000)
- 4 Grant or award Director acquired 1,961 shares (grant or award)
Page 4 of 26 · 512 filings